» Articles » PMID: 35354211

Searching of Clinical Trials Made Easier in CBioPortal Using Patients' Genetic and Clinical Profiles

Overview
Publisher Thieme
Date 2022 Mar 30
PMID 35354211
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Molecular tumor boards (MTBs) cope with the complexity of an increased usage of genome sequencing data in cancer treatment. As for most of these patients, guideline-based therapy options are exhausted, finding matching clinical trials is crucial. This search process is often performed manually and therefore time consuming and complex due to the heterogeneous and challenging dataset.

Objectives: In this study, a prototype for a search tool was developed to demonstrate how cBioPortal as a clinical and genomic patient data source can be integrated with ClinicalTrials.gov, a database of clinical studies to simplify the search for trials based on genetic and clinical data of a patient. The design of this tool should rest on the specific needs of MTB participants and the architecture of the integration should be as lightweight as possible and should not require manual curation of trial data in advance with the goal of quickly and easily finding a matching study.

Methods: Based on a requirements analysis, interviewing MTB experts, a prototype was developed. It was further refined using a user-centered development process with multiple feedback loops. Finally, the usability of the application was evaluated with user interviews including the thinking-aloud protocol and the system usability scale (SUS) questionnaire.

Results: The integration of ClinicalTrials.gov in cBioPortal is achieved by a new tab in the patient view where the genomic profile for the search is prefilled and additional parameters can be adjusted. These parameters are then used to query the application programming interface (API) of ClinicalTrials.gov. The returned search results subsequently are ranked and presented to the user. The evaluation of the application resulted in an SUS score of 83.5.

Conclusion: This work demonstrates the integration of cBioPortal with ClinicalTrials.gov to use clinical and genomic patient data to search for appropriate trials within an MTB.

Citing Articles

Empowering personalized oncology: evolution of digital support and visualization tools for molecular tumor boards.

Strantz C, Bohm D, Ganslandt T, Borries M, Metzger P, Pauli T BMC Med Inform Decis Mak. 2025; 25(1):29.

PMID: 39819625 PMC: 11736948. DOI: 10.1186/s12911-024-02821-8.


Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors.

Kuehn J, Metzger P, Neidert N, Matysiak U, Grassel L, Philipp U NPJ Precis Oncol. 2024; 8(1):180.

PMID: 39143272 PMC: 11324882. DOI: 10.1038/s41698-024-00674-y.


Increased FGF2 expression promotes immune cell infiltration and correlates with an unfavorable prognosis in thyroid cancer.

Chen H, Du X Heliyon. 2024; 10(11):e32272.

PMID: 38873667 PMC: 11170142. DOI: 10.1016/j.heliyon.2024.e32272.


[The Medical Informatics Initiative at a glance-establishing a health research data infrastructure in Germany].

Semler S, Boeker M, Eils R, Krefting D, Loeffler M, Bussmann J Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2024; 67(6):616-628.

PMID: 38837053 PMC: 11166846. DOI: 10.1007/s00103-024-03887-5.


[The collaborative project "Personalized medicine for oncology" (PM4Onco) as part of the Medical Informatics Initiative (MII)].

Metzger P, Boerries M Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2024; 67(6):668-675.

PMID: 38739266 PMC: 11166753. DOI: 10.1007/s00103-024-03886-6.


References
1.
Lipscomb C . Medical Subject Headings (MeSH). Bull Med Libr Assoc. 2000; 88(3):265-6. PMC: 35238. View

2.
Dharod A, Bellinger C, Foley K, Case L, Miller D . The Reach and Feasibility of an Interactive Lung Cancer Screening Decision Aid Delivered by Patient Portal. Appl Clin Inform. 2019; 10(1):19-27. PMC: 8438623. DOI: 10.1055/s-0038-1676807. View

3.
Kaplan C, Napoles A, Dohan D, Hwang E, Melisko M, Nickleach D . Clinical trial discussion, referral, and recruitment: physician, patient, and system factors. Cancer Causes Control. 2013; 24(5):979-88. DOI: 10.1007/s10552-013-0173-5. View

4.
Comis R, Miller J, Aldige C, Krebs L, Stoval E . Public attitudes toward participation in cancer clinical trials. J Clin Oncol. 2003; 21(5):830-5. DOI: 10.1200/JCO.2003.02.105. View

5.
Wain H, Bruford E, Lovering R, Lush M, Wright M, Povey S . Guidelines for human gene nomenclature. Genomics. 2002; 79(4):464-70. DOI: 10.1006/geno.2002.6748. View